Cardiovascular imaging AI firm Elucid has named new executives ahead of the launch of PlaqueIQ, its image analysis software. PlaqueIQ was cleared in October 2024 by the U.S. Food and Drug Administration (FDA).
The company has appointed Amir Ahmadi, MD, as its chief scientific advisor. (He has a financial relationship with Elucid in his role as chief scientific advisor, the company noted.) Ahmadi is a cardiologist at Icahn School of Medicine at Mount Sinai in New York. His ongoing clinical practice and research focus on using CT coronary angiography to detect and treat subclinical atherosclerosis, understand myocardial infarction mechanisms, and investigate the relationship between high-risk plaque features and ischemia, according to the firm.
It has also tapped Carol Holt as its vice president of clinical development; Kevin Mathews as senior vice president of marketing; and Amy Pyke as senior vice president of market access, Elucid said.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
